The global gene editing tool market is on track to advance at a CAGR of 18.4% from 2024 to 2034. In 2024, the valuation is standing around USD 688.1 million and is projected to expand to USD 3,713.1 million by 2034. The industry is set to gain traction during the forecast period owing to the increased prevalence of genetic diseases globally.
Several large investments in the gene editing industry have been seen in recent years. Private equity firms, venture corporations, and governmental agencies are the primary investors in the industry. Behind these large investments, the motive of firms is to secure intellectual properties in a sector that could lead to advances in areas of the biotechnology field. These increased investments are marked as the latest trend in the current markets. This is expected to lead the gene editing tool market during the forecast period as well.
Scientists, as well as researchers, are contributing to the sector by organizing research operations to develop ways to use gene editing to find medication or therapies to treat genetic or acquired diseases. For instance, researchers in the Burgess Lab have worked on zebrafish genomics. They eliminate different genes in zebrafish using CRISPR technology.
Developing regions such as Asia Pacific are ready to gain a prominent industry share owing to ongoing scientific research activities. Countries such as China and India have contributed major growth prospects in recent years. In the aforementioned countries, favorable initiatives toward gene editing and research purposes have been actively promoted by the government itself.
On the other hand, North America and Europe are witnessing steady growth in recent years. These regions have already developed a landscape and skilled working professionals. Additionally, large investments were seen in research and development activities. Also, the presence of prominent players has driven industry growth in recent years in these regions.
| Attributes | Description |
|---|---|
| Estimated Global Gene Editing Tool Market Size (2024E) | USD 688.1 million |
| Projected Global Gene Editing Tool Market Value (2034F) | USD 3,713.1 million |
| Value-based CAGR (2024 to 2034) | 18.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Adoption of Personalized Medicines Revolutionizes the Industry
In the modern era, demand for tailored medical solutions has increased. Medical professionals are heavily prescribing medications according to the patient's genetic makeup in developed regions. By offering promising solutions and enabling precise modifications of genes, personalized medicine is an emerging ideal solution for individuals suffering from genetic disorders.
Gene Editing Tools Face Safety Concerns in Early Stages
Safety concerns are presumed to hamper the gene editing tool market growth during the forecast period. Gene editing tools are a new concept and are still in the early stages of development. They also require skilled health professionals and researchers. While studies indicate there are chances of off-target effects and unintended consequences of gene editing. Professionals must be careful when considering the risks involved.
Synthetic Genes Drive Biotech Opportunities and Tech Advances Boost Diagnostics
The increasing need for synthetic genes in biotechnology domains is expected to create significant opportunities for stakeholders. Rapid technological advances will modernize diagnostic tools in the coming years. Thus, the advancements are anticipated to increase market competition among tool manufacturers during the forecast horizon. Also, creating tools that provide convenience and ease of technology can drive industry sales in the upcoming years.
The gene editing tool market is projected to register a value with an 18.4% CAGR between 2024 and 2034, slightly up from the 17.4% CAGR recorded during 2019 and 2023.
The COVID-19 pandemic outbreak led to the development of highly advanced genome engineering tools for detecting genetic variations in viral strains. Governments are taking action due to health concerns post-COVID. The International Department of the Food and Drug Administration announced a policy for evaluating the impact of viral mutations on COVID-19 tests.
Before the pandemic year, the technologies in the medical department did not have advanced features, and the people and medical services were underdeveloped. After the pandemic, the population and medical services have evolved and gained knowledge to advance medical facilities to deal with this situation and provide high-quality service to individuals.
There have been recent changes made by many governments after the pandemic, and several government bodies are investing in research and development. Ongoing innovation in research and educational institutions for various CRISPR editing tools is expanding business revenue.
Several governments’ demand for gene editing tools impacts the formulation of these editing tools. As the population becomes more health-conscious, they are spending more on high-quality treatment. All these factors are expected to drive sales of gene editing tools in the coming years.
Principal Consultant
In terms of product type, the clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) segment is anticipated to hold a 51.6% industry share in 2024. In addition, in terms of application type, cell line engineering is expected to dominate by holding a share of 42.2% in 2024.
| Segment | Clustered Regularly Interspaced Short Palindromic Repeats (Type) |
|---|---|
| Value Share (2024) | 51.6% |
Based on product type, the CRISPR/Cas9 segment is projected to have the largest share of the gene editing tool market in the coming years. This increase is due to the growing use of CRISPR DNA editing in human-induced pluripotent stem cell (hiPSC)-related initiatives to uncover novel therapeutic options for a variety of disorders.
This method is also predicted to help improve the productivity of CHO cell lines. These cell lines are widely used in the manufacturing of large-molecule therapies, and their strong demand is expected to drive sales of CRISPR genome engineering tools.
| Segment | Cell Line Engineering (Application) |
|---|---|
| Value Share (2024) | 42.2% |
By offering more accurate and reliable disease models, cell line engineering has emerged as an ideal application in the current period. Additionally, cell line engineering provides facilities such as the creation of a model that has all the genetic and physiological features of human diseases.
Thus, by providing a more accurate platform for drug screening and development, cell line engineering has gained popularity among researchers in recent years. Moreover, the demand for personalized medicines is anticipated to lead the segment to growth in the coming years, as the cell line allows researchers to identify genetic mutations and develop tailored medicine.
The biotechnology industry is expected to show greater potential in several regions, with Europe standing out with high potential. With a remarkable CAGR, the United Kingdom will gain a key industry share in the gene editing tool market during the forecast period. The growth drivers of specific countries with deep research are well elaborated below.
| Countries | CAGR 2024 to 2034 |
|---|---|
| United States | 20.7% |
| Germany | 21.7% |
| United Kingdom | 23.2% |
| India | 14.2% |
| Russia | 16.1% |
The gene editing tool market in the United States is anticipated to exhibit prospective growth, with a projected CAGR of 20.7% in the coming years. The United States has experienced significant growth and leads in gene editing tools. Several industries, such as Editas Medicine and CRISPR Therapeutics, are pioneering CRISPR-based therapies.
In the United States, advanced research facilities like the Broad Institute and NIH drive continuous innovation. Collecting funds from capitalists and government grants fosters development. The collaboration between academic and industry sectors, as seen in innovative genomics institutes working with biotech firms, accelerates innovation. This type of activity boosts the revenue growth of the gene editing tool sector globally.
The gene editing tool market in India is expected to maintain steady growth, with an anticipated CAGR of 14.2% until 2034, signaling a positive outlook. Gene editing tools are gaining popularity among people, with startups promoting their application. Startups like Pandorum Technologies are focusing on creating regenerative medicine.
Research institutions are acquiring knowledge about various tools to innovate new products. Institutes involved, such as Genomics and Integrative Biology, contribute to advancement. India's regulatory framework for gene editing is still evolving, with guidelines set by the Department of Biotechnology. On the other hand, ethical considerations and public debate are fueled by policy decisions. India's diverse genetic pool presents opportunities for personalized and agricultural development.
The gene editing tool market in Russia is presumed to maintain growth, with a CAGR of 16.1%. The growing innovation in gene editing tools in Russia is evident due to high investment in this field by industries. Also, Russia's increasing population provides a vast range of applications for gene editing tools, from disease treatment to improvements in agriculture.
Various genetic problems arise in Russia due to the aging population, requiring advanced treatments and high-quality tools. In response, Russia's government is taking steps to develop highly advanced technologies and equipment in the medical sector, aiming to offer a high level of service to individuals. This initiative contributes to the thriving expansion of the gene editing tools industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Gene editing tool market players are constantly researching gene technology to update their tools. Companies are working on developing more efficient and accurate tools that can be used in clinical trials and eventually approved by regulatory agencies. Companies such as CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine are leading the way in developing gene editing technologies that can be used to treat a variety of genetic disorders.
Industry Updates
The type segment is divided into clustered regularly interspaced short palindromic repeats (CRISPR/Cas9), zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), viral systems, transposon systems, and others.
Gene editing tools find application in veterinary medicine, cell line engineering, bioremediation, food and brewing development, food waste management, bio-sensing development, and others.
End use industries present in this industry are biotech and pharma companies, contract research organizations, academic and research institutes, food, and others.
Regional analysis is conducted across key countries of in North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa.
The CAGR of the industry in Germany is estimated to be 21.7% through 2034.
The industry is expected to progress at a CAGR of 18.4% through 2034.
The industry is expected to be worth USD 688.1 million in 2024.
The CAGR of the industry in the United States is estimated to be 20.7% through 2034.
The industry is estimated to get as big as USD 3,713.1 million by 2034.
1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
5. Pricing Analysis
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
6.1. Product
6.2. Application
6.3. End User
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
7.1. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9)
7.2. Zinc Finger Nucleases (ZFNs)
7.3. Transcription Activator-Like Effector Nucleases (TALENs)
7.4. Viral Systems
7.5. Transposon Systems
7.6. Others
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
8.1. Veterinary Medicine
8.2. Cell Line Engineering
8.3. Bioremediation
8.4. Food and Brewing Development
8.5. Food Waste Management
8.6. Bio Sensing Development
8.7. Others
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
9.1. Biotech and Pharma Companies
9.2. Contract Research Organizations
9.3. Academic and Research Institutes
9.4. Food Industry
9.5. Others
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
10.1. North America
10.2. Latin America
10.3. Western Europe
10.4. South Asia
10.5. East Asia
10.6. Eastern Europe
10.7. Middle East & Africa
11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
14. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
18. Sales Forecast 2024 to 2034 by Product, Application, and End User for 30 Countries
19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
20. Company Profile
20.1. Thermo Fisher Scientific, Inc.
20.2. ERS Genomics
20.3. CRISPR Therapeutics
20.4. Merck KGaA
20.5. Editas Medicine
20.6. GE Healthcare Dharmacon Inc.
20.7. Takara Bio USA
20.8. New England Biolabs
20.9. Horizon Discovery Group plc
20.10. Intellia Therapeutics, Inc.
20.11. GenScript Biotech Corporation
Explore Healthcare Insights
View Reports
Gene Editing Tool Market
